Parkinson's Disease Center and Movement Disorders Clinic

Similar documents
Hemifacial spasm. Parkinson's Disease Center and Movement Disorders Clinic

Parkinson's Disease Center and Movement Disorders Clinic

Parkinson's Disease Center and Movement Disorders Clinic

THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN

IN ADUL T SUBJECTS WITH BLEPHAROSPASM ACROSS DOSING INTE R VAL S

Source: *Dystonia facts medically edited by: Charles Patrick Davis, MD, PhD

Apraxia of eyelid opening: Clinical features and therapy

Articles Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis

Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm

Scottish Medicines Consortium

Clinical Outcomes of Individualized Botulinum Neurotoxin Type A Injection Techniques in Patients with Essential Blepharospasm

Dystonias. How are the dystonias classified? One way of classifying the dystonias is according to the parts of the body they affect:

Does Prolonged Botulinum Toxin A Treatment Decrease its Duration of Action?

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Clinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: ERX.SPA.194 Effective Date:

GENETICS AND TREATMENT OF DYSTONIA

Harald Hefter, 1 Christian Hartmann, 1 Ulrike Kahlen, 1 Marek Moll, 1 Hans Bigalke 2

See Important Reminder at the end of this policy for important regulatory and legal information.

Botox , The Patient Education Institute, Inc. rxf60101 Last reviewed: 01/11/2018 1

This guide describes some of the important facts about Neurobloc that you need to be aware of, however, it does not replace the advice given to you

Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct)

Professor Tim Anderson

Dystonia: Title. A real pain in the neck. in All the Wrong Places

For peer review only. BMJ Open. For peer review only -

Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia

Diagnostic Delays in Spasmodic Dysphonia: A Call for Clinician Education

BOTOX Cosmetic (onabotulinumtoxina) before-and-after

Neuromuscular Blocking Agents

Professor Tim Anderson

Understanding Dystonia

See Important Reminder at the end of this policy for important regulatory and legal information.

BOTOX Cosmetic (onabotulinumtoxina) before-and-after photo files

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Parkinson's Disease Center and Movement Disorders Clinic

THE MEDICAL AND SURGICAL TREATMENT OF DYSTONIA

MEDICATION GUIDE BOTOX BOTOX Cosmetic (Boe-tox) (onabotulinumtoxina) for Injection

DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex)

The blink reflex recovery cycle differs between essential and presumed psychogenic blepharospasm

BOTOX (onabotulinumtoxina) for Therapeutic Use

Diagnosis and treatment of dystonia

MERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS

DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex)

Diagnosis and treatment of dystonia

Neurological disorders. Dystonia Search date September 2013 Ailsa Snaith and Derick Wade ...

Clinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: CP.PHAR.231

Hubert H. Fernandez, MD

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 4/2/19. IncobotulinumtoxinA

Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc )

Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection

Assessment of health related quality of life in patients with hemifacial spasm

See Important Reminder at the end of this policy for important regulatory and legal information.

200 SW 8 th St, STE A, Ocala, FL PH: FAX: Dr. Omar Garcia, Medical Director

Please see Approved Uses and Important Safety Information, including Boxed Warning, inside.

See Important Reminder at the end of this policy for important regulatory and legal information.

Medication Prior Authorization Form

Clinical Study Comparison of Two Botulinum Neurotoxin A Injection Patterns with or without the Medial Lower Eyelid in the Treatment of Blepharospasm

M0BCore Safety Profile

Double-Blind, Randomized, Comparative Study of Meditoxin Versus Botox in the Treatment of Essential Blepharospasm

Blepharospasm (eyelid spasm)

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)

Botox. Botox (onabotulinum toxin A) Description

CEDAC FINAL RECOMMENDATION

Spasmodic dysphonia Symptoms

Headache and Migraine Treatment

Important Safety Information

Clinical Analysis of Blepharospasm and Apraxia of Eyelid Opening in Patients with Parkinsonism

Original Article Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm

Moving fast or moving slow: an overview of Movement Disorders

Antibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications

Uncovering Pain in Parkinson s

Pallidal Deep Brain Stimulation

Sustained efficacy and safety of repeated incobotulinumtoxina (Xeomin Ò ) injections in blepharospasm

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Please see Important Safety Information, including Boxed Warning, inside.

Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies

DMRF CANADA THE DYSTONIA SURVEY REPORT

CONSUMER MEDICINE INFORMATION

MYOBLOC and Cervical Dystonia A Patient s Guide

BOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011

D. M. Simpson, A. Blitzer, A. Brashear, et al. DOI /01.wnl This information is current as of May 5, 2008

ORIGINAL CONTRIBUTION. Sensory Modulation of the Blink Reflex in Patients With Blepharospasm. exhibit an abnormal excitability of the blink reflex

Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm

Journal of Anesthesia & Pain Medicine

Disclaimer. All information shared in this presentation is in the public domain.

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)

Botuli focal d THERAPEUTIC INTERVENTION

Cynthia was treated for her frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside.

Table of Contents. Preface... xi. Part I: Introduction to Movement Disorders

Atropine eye drops for treatment of a lazy eye

Andy was treated for frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside.

Learn Connect Succeed. JCAHPO Regional Meetings 2017

Advanced Treatment of Spasticity 14 th Jan 2017

Ophthalmology. Common Eyelid Problems

ALTERNATIVE TREATMENTS

DYSTONIA. Mysi05/Shutterstock

Dr Barry Snow. Neurologist Auckland District Health Board

Movement Disorders- Parkinson s Disease. Fahed Saada, MD March 8 th, th Family Medicine Refresher Course St.

Informed Consent Botulina Toxins Botox, Dysport, Xeomin Neurotoxins

Quantitative Assessment of Botulinum Toxin Treatment in 43 Patients with Head Tremor

NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - ORIGINAL ARTICLE

Transcription:

Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Blepharospasm Diagnosis Involuntary facial movements have been recognized for long time and were depicted by artists who were fascinated how these movements distorted the facial expression. For example, in the 16th century, the Flemish artist Brueghel painted a woman with apparent blepharospasm and involuntary jaw opening. Although the eponym "Meige's syndrome" is still occasionally used to designate the combination of blepharospasm (involuntary eye closure) and oromandibular dystonia (involuntary jaw and mouth spasms), a more appropriate term to describe this combination is cranial dystonia. The term dystonia means involuntary sustained, patterned, twisting, pulling or squeezing movements. One of the most common types of adult-onset focal dystonia is blepharospasm. Blepharospasm is a neurological, not an ophthalmological, disorder as there is usually no abnormality with the eyes on careful eye examination. Many patients are initially misdiagnosed as having "dry eyes" but eye drops or lubricants rarely provide any benefit. About one-third of blepharospasm patients report increased frequency of blinking, commonly associated with a feeling of irritation in the eyes and light sensitivity (photophobia). The blinking usually progresses to more sustained contractions of the orbicularis oculi (eyelid muscles) leading to forceful closure of eyelids. Blepharospasm is usually exacerbated by bright light (photophobia) and, as a result, many patients wear sunglasses both outside and inside. The spasms may be transiently alleviated by pulling on an upper eyelid or an eyebrow, pinching the neck, talking, humming, yawning, singing, sleeping, relaxation, reading, concentration, looking down and other alleviating maneuvers. Blepharospasm may vary in severity from only a slightly annoying or embarrassing 1

condition to a disabling disorder that may render the patient functionally blind and interfere with daily activities such as reading, watching television, and driving. Blepharospasm is seldom an isolated condition; this form of dystonia is often associated with dystonia in other facial, jaw, or neck muscles leading to "cranialcervical dystonia. In some patients, the dystonia spreads to involve the vocal cords (spasmodic dysphonia), trunk and limbs. Cause Blepharospasm may be associated to exaggerated neuroplasticity and although usually sporadic (without family history), genetic mechanisms many be involved, as they often are in other forms of dystonia Treatment Botulinum toxin (BTX) injections into the eyelids and eyebrows are now considered the treatment of choice for blepharospasm, providing moderate to marked improvement in over 90% of patients. The average latency from the time of the BTX injection to the onset of improvement is 2-5 days and the average duration is 3-4 months, after which time the treatment must be repeated in order to sustain the benefit. In addition to the marked functional improvement, there is usually a meaningful amelioration of discomfort and, because of less embarrassment, the patients' self-esteem also frequently improves. Although about 10-15% of all treatment sessions are followed by some side effects (droopiness of eye lid, blurring of vision or double vision, tearing, and local hematoma), the complications only rarely affect patient's functioning and usually resolve spontaneously in less than two weeks. There is no apparent decline in benefit and the frequency of complications actually decreases after repeat BTX treatments. Aproclonidine, an eye drop that can cause contraction of the upper eyelid muscle, can be used as a temporary measure while the BTX effect has not started or when it is wearing off. 3

Some patients with blepharospasm have partial relief from medications such as clonazepam, trihexyphenidyl, lorazepam, baclofen and tetrabenazine. However, given their side effects and the significant improvement with BTX, oral medications are not frequently used. In very severe cases in patients with significant functional impairment who have not responded well to botulinum toxin, surgery may be another option. A myectomy, which involves removal of some or all of the muscles responsible for eyelid closure, may be considered. The suspension of the a muscle in the forehead with synthetic threads evaluated in refractory cases with good results in a small study, but the use of this technique in a larger numbers or patients is warranted. The use of deep brain stimulation was also reported in small studies, with success in refractory cases of blepharospasm associated or not with other craniocervical dystonias. Selected References Dressler D, Karapantzou C, Rohrbach S, Schneider S, Laskawi R. Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results. J Neural Transm. 2017;124(2):253-257. Evinger C. Benign essential blepharospasm is a disorder of neuroplasticity: lessons from animal models. J Neuroophthalmol. 2015;35(4):374-379. Fernandez HH, Pagan F, Danisi F, Greeley D, Jankovic J, Verma A, Sethi K, Pappert EJ, XCiDaBLE Study Group. Tremor Other Hyperkinet Mov (NY). 2013;3:1-13. Fernandez HH, Jankovic J, Holds JB, Lin D, Burns J, Verma A, Sethi K, Pappert EJ. Observational study of IncobotulinumtoxinA for cervical dystonia or blepharospasm (XCiDaBLE): interim results for the first 170 subjects with blepharospasm. Tremor Other Hyperkinet Mov (NY). 2014;4:1-8. Forget R, Tozlovanu V, Iancu A, Boghen D. Botulinum toxin improves lid opening in blepharospasm-associated apraxia of lid opening. Neurology. 2002;58:1843-6. 4

Hallet M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114. Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol. 2003;87:54-6. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxina (NT 201, Xeomin) in the treatment of blepharospasm: a randomized trial. Mov Disord. 2011;26:1521-8. Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131-1138. Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2017. [Epub ahead of print] Jost WH, Benecke R, Hauschke D, Jankovic J, Kañovsky P, Roggenkämper P, Simpson DM, Comella CL. Clinical and pharmachological properties of IncobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015;9:913-926. Peckham EL, Lopez G, Shamim EA, et al. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol. 2011;18:382-6. Pirio Richardson S, Wegele AR, Skipper B, Deligtisch A, Jinnah HA, Dystonia Coalition Investigators. Neurology. 2017;88(6):543-550. Ramirez-Castaneda J, Jankovic J. Toxicon. 2014;90:344-348. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Groseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. Vijayakumar D, Wijemanne S, Jankovic J. Treatment of blepharospasm with aproclonidine. J Neurol Sci. 2017;372:57-59. Wang X, Zhang C, Wang Y, Liu C, Zhao B, Zhang JG, Hu W, Shao X, Zhang K. Deep brain stimulation for craniocervical dystonia (Meige Syndrome): a report of 5

four patients and a literature-based analysis of its treatment effects. Neuromodulation. 2016;19(8):818-823. Yamada K, Shinojima N, Hamasaki T, Kuratsu J. Pallidal stimulation for medically intractable blepharospasm. BMJ Case Rep. 2016. Support Organization Benign Essential Blepharospasm Research Foundation P.O. Box 12468 Beaumont, TX 77726-2468 Phone: (409) 832-0788 Fax: (409) 832-0890 Email: bebrf@blepharospasm.org https://www.blepharospasm.org/ 6